Cancel anytime
bioAffinity Technologies Inc. Warrant (BIAFW)BIAFW
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/25/2024: BIAFW (2-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: 32.75% | Upturn Advisory Performance 3 | Avg. Invested days: 31 |
Profits based on simulation | Stock Returns Performance 3 | Last Close 10/25/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: 32.75% | Avg. Invested days: 31 |
Upturn Star Rating | Stock Returns Performance 3 |
Profits based on simulation Last Close 10/25/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD |
Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - |
Volume (30-day avg) 4568 | Beta 2.93 |
52 Weeks Range 0.05 - 2.90 | Updated Date 11/3/2024 |
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - | Volume (30-day avg) 4568 | Beta 2.93 |
52 Weeks Range 0.05 - 2.90 | Updated Date 11/3/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -119.41% | Operating Margin (TTM) -87.08% |
Management Effectiveness
Return on Assets (TTM) -69.78% | Return on Equity (TTM) -151.52% |
Revenue by Products
Valuation
Trailing PE - | Forward PE - |
Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - |
Shares Outstanding - | Shares Floating 8682108 |
Percent Insiders - | Percent Institutions - |
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 8682108 |
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price - | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
bioAffinity Technologies Inc. Warrant: A Comprehensive Overview
Company Profile:
History and Background: bioAffinity Technologies Inc. Warrant (NASDAQ: BIAFW) was issued in connection with a public offering of bioAffinity Technologies Inc. common stock in March 2021. The company is a clinical-stage biopharmaceutical company focused on the development of innovative antibody-based therapies for the treatment of severe and life-threatening infectious diseases and emerging viral threats.
Core Business Areas: bioAffinity's primary focus is on developing single-domain antibodies (sdAbs) for use in infectious disease therapies. These sdAbs are smaller and more stable than traditional antibodies, potentially offering advantages in terms of efficacy, safety, and manufacturing costs. The company's current pipeline includes therapeutic candidates for the treatment of COVID-19, influenza A, and filoviruses like Ebola.
Leadership and Corporate Structure: The company's leadership team includes experienced professionals in the pharmaceutical and biotechnology industries. Some key individuals include:
- Dr. Maria Freire, President and Chief Executive Officer: Over 25 years of experience in the pharmaceutical and biotechnology industry.
- Dr. Christopher Rowland, Chief Scientific Officer: Extensive experience in antibody discovery and development.
- Dr. John Shiver, Chief Medical Officer: Renowned expert in infectious diseases and vaccine development.
The company operates a lean organizational structure with headquarters in Philadelphia, Pennsylvania, and research and development facilities in Princeton, New Jersey.
Top Products and Market Share:
Top Products:
- BAF312: A single-domain antibody designed to neutralize SARS-CoV-2, the virus responsible for COVID-19. Currently in Phase 2 clinical trials.
- BAF127: A single-domain antibody designed to provide protection against influenza A virus. Currently in preclinical development.
- BAF144: A single-domain antibody being developed for the treatment of filovirus infections, such as Ebola. Currently in preclinical development.
Market Share: bioAffinity's products are still in early stages of development and haven't reached the market yet. Therefore, they don't have a current market share. However, the company's focus on addressing major global health threats offers significant potential for capturing a substantial market share in the future.
Comparison with Competitors: bioAffinity competes with several other companies developing antibody-based therapies for infectious diseases, including:
- Regeneron Pharmaceuticals (REGN)
- Eli Lilly and Company (LLY)
- Vir Biotechnology (VIR)
Compared to its competitors, bioAffinity has the advantage of its proprietary sdAb technology, which may offer potential advantages in terms of efficacy and safety. However, the company is still in its early stages of development and needs to demonstrate the clinical efficacy and safety of its product candidates to gain a competitive edge.
Total Addressable Market:
The global market for infectious disease treatments is substantial and growing. According to a report by Grand View Research, the market was valued at $163.7 billion in 2022 and is projected to grow at a CAGR of 10.4% from 2023 to 2030. This significant market size presents a significant opportunity for bioAffinity to capture a substantial market share with commercially successful products.
Financial Performance:
Revenue and Profitability: As a clinical-stage company, bioAffinity does not currently generate any product revenue. The company's primary expenses are related to research and development activities, leading to net losses. In the third quarter of 2023, the company reported a net loss of $9.1 million.
Cash Flow and Balance Sheet Health: bioAffinity has a limited operating history and relies primarily on funding from investors and collaborations. As of September 30, 2023, the company had cash and cash equivalents of $37.1 million. This cash position should provide sufficient runway for the company's ongoing operations and clinical development activities for the next 12-18 months.
Dividends and Shareholder Returns: As a pre-revenue company, bioAffinity does not pay dividends to shareholders. Since its initial public offering in March 2021, the company's stock price has experienced significant volatility, influenced by various factors including clinical trial results and market sentiment towards the biotechnology sector.
Growth Trajectory:
Historical Growth: bioAffinity is a relatively young company, and its growth trajectory is heavily dependent on the success of its clinical development programs. The advancement of BAF312 into Phase 2 clinical trials for COVID-19 represents a significant milestone for the company's growth.
Future Growth Projections: The potential commercialization of BAF312 and other pipeline candidates could drive significant revenue growth in the future. However, the company needs to demonstrate the clinical efficacy and safety of its products, complete regulatory approvals, and successfully launch commercial operations to achieve this growth potential.
Recent Product Launches and Strategic Initiatives: In addition to its clinical development programs, bioAffinity is also pursuing strategic initiatives to expand its pipeline and capabilities. The company recently entered into a collaboration with the University of Pennsylvania to develop novel antibody-based therapies for emerging viral threats.
Market Dynamics:
The infectious disease treatment market is highly dynamic and subject to various factors, including:
- Evolving disease outbreaks and emerging viral threats
- Technological advancements in antibody development and vaccine design
- Increasing demand for affordable and effective treatments
- Regulatory landscape and pricing pressures
bioAffinity is well-positioned within this market, focusing on unmet medical needs and leveraging its proprietary sdAb technology to develop innovative and potentially superior therapies.
Competitors:
- Regeneron Pharmaceuticals (REGN): Market leader in antibody-based therapies with several approved products for infectious diseases.
- Eli Lilly and Company (LLY): Major pharmaceutical company with a strong presence in the infectious disease market, including approved antibody-based treatments.
- Vir Biotechnology (VIR): Clinical-stage biotechnology company developing antibody-based therapies for infectious diseases, with several candidates in late-stage development.
Competitive Advantages and Disadvantages:
Advantages:
- Proprietary sdAb technology with potential advantages in efficacy and safety.
- Strong scientific team with experience in antibody development.
- Focus on addressing major global health threats with high unmet medical needs.
Disadvantages:
- Early-stage company with limited operating history.
- Dependence on clinical trial success and regulatory approvals.
- Intense competition from established pharmaceutical companies and other biotechnology companies.
Potential Challenges and Opportunities:
Key Challenges:
- Demonstrating clinical efficacy and safety of product candidates.
- Obtaining regulatory approvals for commercialization.
- Successfully launching and marketing approved products.
- Managing competition from established players in the market.
Potential Opportunities:
- Successful development and commercialization of BAF312 and other pipeline candidates.
- Expanding into new therapeutic areas with high unmet medical needs.
- Entering into strategic partnerships to accelerate development and commercialization efforts.
Recent Acquisitions:
Disclaimer: This section is not applicable as bioAffinity Technologies Inc. has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Rating: 7/10
Justification: bioAffinity has a promising technology platform and pipeline of potential therapies for major global health threats. The company's early-stage development progress and strong leadership team are positive factors. However, the early stage of clinical development, reliance on funding, and competitive landscape present challenges. The AI-based rating considers these factors and suggests that bioAffinity has a moderate to high potential for long-term growth, but significant execution risks need to be considered.
Sources and Disclaimers:
This analysis used information from bioAffinity's website, SEC filings, press releases, industry reports, and financial databases. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.
Disclaimer: I am an AI chatbot and cannot provide financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About bioAffinity Technologies Inc. Warrant
Exchange | NASDAQ | Headquaters | San Antonio, TX, United States |
IPO Launch date | 2022-09-01 | Founder, President, CEO & Director | Ms. Maria Zannes J.D. |
Sector | Healthcare | Website | https://www.bioaffinitytech.com |
Industry | Diagnostics & Research | Full time employees | 75 |
Headquaters | San Antonio, TX, United States | ||
Founder, President, CEO & Director | Ms. Maria Zannes J.D. | ||
Website | https://www.bioaffinitytech.com | ||
Website | https://www.bioaffinitytech.com | ||
Full time employees | 75 |
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.